Partner David Rosen was quoted in an article in Regulatory Focus, “FDA Plans Hearing on Biosimilar Competition, Development,” about the U.S. Food and Drug Administration’s plan to hold a public hearing to gather input on how it can facilitate the development of biosimilars and help bring them to market in a timely fashion.
Rosen said the legal issues delaying the launch of biosimilars are outside the FDA’s purview. “That’s in the hands of the courts and the companies that are involved,” he said.
He also said that the FDA could have a greater impact on competition by facilitating the development of more biosimilars, which in turn could lead to lower prices for products with multiple biosimilar competitors.
Rosen said the legal issues delaying the launch of biosimilars are outside the FDA’s purview. “That’s in the hands of the courts and the companies that are involved,” he said.
He also said that the FDA could have a greater impact on competition by facilitating the development of more biosimilars, which in turn could lead to lower prices for products with multiple biosimilar competitors.
People
Related News
27 August 2024
In the News
Samuel Goldstick Assesses Data Privacy Challenges for Automakers
Foley & Lardner LLP partner Samuel Goldstick underscored how disclosure can help automakers reduce legal risk in the Automotive Dive article, "Automakers face growing data privacy challenges, experts say."
26 August 2024
In the News
Judith Waltz Quoted on Inflation Reduction Act, Pharma Impact
Foley & Lardner LLP partner Judith Waltz is quoted in the PharmaVoice article, "Pharmas’ IRA court losses mount. They keep pursuing them."
20 August 2024
In the News
Kevin Hyde Featured in Q&A on Jacksonville Legal Market – 'The outlook is good'
Foley & Lardner LLP partner Kevin Hyde is featured in a Capital Analytics Associates Q&A on the major achievements of Foley's Jacksonville office, key trends in the legal market, and the firm's commitment to its talent and client service.